pradigastat

Small moleculeexperimental

Clinical trial activity

11 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
9
Phase 3
2
Phase 4
0

Earliest trial started Apr 1, 2009 (NCT00901979)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(O)C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1
Mol. weight
455.48 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • lcq908
  • lcq908
  • lcq908
  • lcq908-nxa
  • lcq908-nxa
  • pradigastat
  • pradigastat
  • pradigastat
  • pradigastat
  • pradigastat

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04620161Phase 2Sep 22, 2020Covance, Guangzhou Anjie Biomedical Technology Co., Ltd.
NCT01811472Phase 2Jun 1, 2013Novartis
NCT01589237Phase 3Feb 1, 2013Novartis
NCT01514461Phase 3Jul 1, 2012Novartis
NCT01594983Phase 2Jun 1, 2012Novartis
NCT01558323Phase 1May 1, 2012Novartis
NCT01594957Phase 1Apr 1, 2012Novartis
NCT01474434Phase 2Dec 1, 2011Novartis
NCT01387958Phase 2Jul 1, 2011Novartis
NCT01146522Phase 1/Phase 2 (Phase 2)May 1, 2010Novartis
NCT00901979Phase 2Apr 1, 2009Novartis
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovartisFor profit101032009
CovanceFor profit1012020
Guangzhou Anjie Biomedical Technology Co., Ltd.Government1112020
3 organizations
Page 1 / 1